Back to Journals
Lung Cancer: Targets and Therapy
Chao Family Comprehensive Cancer Center, Department of Medicine-Hematology/Oncology, University of California Irvine School of Medicine, United States
Editor-in-Chief: Professor Sai-Hong Ignatius Ou
Professor Sai-Hong Ignatius Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served an an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.
Dr. Ou is one of the eight original phase 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publication in New Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou is on the scientific advisor board of TP Therapeutics which is developing the fourth generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer research and have been ad hoc reviewer for New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer for the American Society of Clinical Oncology annual meeting from 2016-2018.
AntĂłnio AraĂşjo, Head of the Department of Medical Oncology, Centro Hospitalar do Porto, Professor in Clinical Oncology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal.
David A Boothman, Professor of Biochemistry and Mol Biology, Indiana University, Indianapolis, IN, USA
Esther Chang, Professor of Oncology, Georgetown University Medical Center, Washington, DC, USA
Haiying Cheng, MD, PhD, Assistant Professor, Department of Medical Oncology, Albert Einstein College of Medicine/Montefiore Medical center, New York, NY, USA.
Fung-Lung Chung, Professor, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Eugenie S Kleinerman, M.D.; Professor, Division of Pediatrics; Professor, Department of Cancer Biology; Mary V. and John A. Reilly Distinguished Chair, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Ying Liang M.D., Ph.D.;Associate Professor,Department of Medical Oncology,Sun Yat-sen University Cancer (SYSUCC), Guang Zhou, P.R. China, 510000.
Joseph Locker, Professor, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Misako Nagasaka, MD, Assistant Professor, Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan USA.
Rajagopal Ramesh, Professor of Pathology, Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Jack A Roth, Professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director, W.M. Keck Center for Innovative Cancer Therapies, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Natthaya Triphuridet, Medical Pulmonologist, Department of Internal Medicine, Chulabhorn Hospital, Bangkok, Thailand.
Frederick A Valeriote, Professor, Division of Hematology and Oncology, Department of Internal Medicine, Director, Drug Discovery and Development Program, Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, USA
Bernard Weissman, Professor of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Fengying Wu, MD PhD, Associate Professor in Department of Oncology, Shanghai pulmonary hospital, Medical School of Tongji University, Shanghai, China.
Reen Wu, Professor, Internal Medicine, School of Medicine, University of California at Davis, Davis, CA, USA
Jian-Ting Zhang, Andrew and Peggy Thomson Chair in Hematology/Oncology, Professor of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Viola Zhu, MD PhD, Assistant Clinical Professor of Medicine, Chao Family Comprehensive Cancer Center, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA.
Yue Zou, Professor, Department of Biochemistry and Molecular Biology, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA